<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="575">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425707</url>
  </required_header>
  <id_info>
    <org_study_id>14-2020/3</org_study_id>
    <nct_id>NCT04425707</nct_id>
  </id_info>
  <brief_title>Ivermectin In Treatment of COVID 19 Patients</brief_title>
  <official_title>The Use of Ivermectin In the Treatment of COVID 19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health and Population, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health and Population, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of
      the patients could not acheive viral clearence with the standard module of care teh idea of
      introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin
      had shown a promising results in vitro studies and in limited in vivo studies. this clinical
      trial may open a new hope for COVID 19 patients as a new and cheap line of treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the study will compare the effect of ivermectin in comaprison and addition to the standard
      mode of care for the COVID 19 patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the role of Ivermectin as a line of treatment for COVID 19</measure>
    <time_frame>2 months</time_frame>
    <description>the role of ivermectin in the cure of COVID 19 patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To asses the rate of viral clearance in comparison to other treatment protocols.</measure>
    <time_frame>2 months</time_frame>
    <description>to compare the results of ivermectin with the standard care</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>A ivermectin alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ivermectin will be administarted alone to COVID 19 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B standard care alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard care will be administarted alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C ivermectin added to standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ivermectin will be administarted in adition to standard care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>use of Ivermectin in the treatment of COVID 19 patients, in comparison to and in addition to the standard care of treatment of COVID 19 in Egypt</description>
    <arm_group_label>A ivermectin alone</arm_group_label>
    <arm_group_label>B standard care alone</arm_group_label>
    <arm_group_label>C ivermectin added to standard of care</arm_group_label>
    <other_name>hydroxychloroquine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral
             RNA swap

        Exclusion Criteria:

          -  Contraindications for the drug: hypersensitivity.

          -  Any medications with possible drug interactions.

          -  Severe cases.

          -  Any malignant condition.

          -  Pregnant females.

          -  Breast feeding females.

          -  Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to
             potential severe drug interaction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>houssam ho masoud, MD</last_name>
    <role>Study Director</role>
    <affiliation>COVID sceintific comittee ministry of health and population</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ehab ah kamal, MD</last_name>
    <phone>01006162663</phone>
    <email>ehabkamal2011@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>noha mo asem, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>isolation and referal hospitals for COVID 19 patients</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ehab ah kamal, MD</last_name>
      <phone>01006162663</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health and Population, Egypt</investigator_affiliation>
    <investigator_full_name>Dr. Ehab kamal</investigator_full_name>
    <investigator_title>general director of fever hospitals</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

